Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06976606 · ClinicalTrials.gov registry record
A Study to Assess Real-world Patient Characteristics and Clinical Course for Symptomatic Patients With PKP2-ACM
A clinical trial of Arrhythmogenic Cardiomyopathy and PKP2-ACM, sponsored by Lexeo Therapeutics.
- Recruiting
- Registry status
- 40
- Enrollment target
- 6
- Study locations
NCT06976606 is a study of Arrhythmogenic Cardiomyopathy and PKP2-ACM that is actively recruiting participants, run by Lexeo Therapeutics. The registered enrollment target is 40 participants. The trial reports 6 study locations across 4 states.
The verdict
NCT06976606, a study of Arrhythmogenic Cardiomyopathy and PKP2-ACM, is actively recruiting participants, sponsored by Lexeo Therapeutics.
- RECRUITING
- Registry status
- 40 participants
- Enrollment target
- 6
- Study locations
Study Summary
An observational study to assess real-world patient characteristics and clinical course of disease in participants with PKP2-ACM.
Conditions Studied
Study Locations (6)
Maryland
- Johns Hopkins University - Baltimore
- Northshore University Healthsystem Research Institute - Columbia
Michigan
- University of Michigan - Ann Arbor
- Henry Ford Hospital - Detroit
California
- Leland Stanford Junior University - Redwood City
New York
- University of Rochester - Rochester
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2024-01-23 |
| Est. Completion | 2027-09 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06976606
The ClinicalTrials.gov registry entry for NCT06976606 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Lexeo Therapeutics, which has 6 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Arrhythmogenic Cardiomyopathy appearing as the primary indexed condition, and to 0 interventions.
NCT06976606 reports 6 study locations spanning 4 distinct geographic areas - top geographies include Maryland, Michigan, California.
Frequently Asked Questions
What is clinical trial NCT06976606 about?
NCT06976606 is a clinical study titled "A Study to Assess Real-world Patient Characteristics and Clinical Course for Symptomatic Patients With PKP2-ACM". An observational study to assess real-world patient characteristics and clinical course of disease in participants with PKP2-ACM.
What is the current status of trial NCT06976606?
This trial is currently recruiting. The enrollment target is 40 participants. The study started on 2024-01-23. Estimated completion is 2027-09.
What conditions does trial NCT06976606 study?
This clinical trial studies the following conditions: Arrhythmogenic Cardiomyopathy, PKP2-ACM, PKP2-ARVC.
Who is sponsoring clinical trial NCT06976606?
This trial is sponsored by Lexeo Therapeutics, which has 6 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06976606 being conducted?
This trial has 6 study locations across California, Maryland, Michigan, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Arrhythmogenic Cardiomyopathy
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.